Loading...

MIRA MIRA PHARMACEUTICALS INC Expansion Plans 8-K Filing

MR P

MR

MIRA PHARMACEUTICALS INC

(MIRA)

2025 8-K

Stock Offering Increase

Clinical Trial Update

Stock Offering Completed

Mira-55 Success

Company Acquisition

Phase 1 Results

Positive PTSD Data

Shareholder Meeting Results

Ketamir-2 Trial Update

Clinical Trials

Clinical Trials

Equity Offerings

Asset Acquisitions

Asset Acquisitions

Asset Acquisitions

Clinical Trials

Product Expansion

Positive Study Results

Clinical Trial Launch

Acquisition Agreement

Product Development

Clinical Trial Approval

Accounting Firm Change

Drug Safety Validation

Management Changes

Clinical Trial Announcement

Ketamir-2 Efficacy

Ketamine Study Results

Annual Meeting Results

Drug Development Update

Preclinical Success

Compliance Regained

Preclinical Study Data on K...

Preclinical Success

Delisting Notice

Changes in Management

Board Restructuring and Res...

Discovery of New Molecule

Resignation of Director

Appointment and Resignation

License Agreement and Loan ...

Appointment and Resignation...

Amendment to Employment Agr...

Public Offering

External Links:

Mira Pharmaceuticals reported positive results from a study of its drug candidate, Ketamir-2, showing it restores normal behavior in stressed rats. The event was reported on September 15, 2025, and supports ongoing development for PTSD and neuropathic pain.

AI Assistant

MIRA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.